Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy

Osama Elsallabi, Vijaya R Bhatt, Prajwal Dhakal, Kirk W Foster, Ketki K Tendulkar

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) is a fatal, multifactorial disorder, which may present with thrombocytopenia, hemolysis, acute renal failure, mental status changes and involvement of other organs. The pathogenesis of TA-TMA is complex and includes multiple risk factors such as certain conditioning regimens, calcineurin inhibitors (CNIs), graft-versus-host disease (GVHD), human leukocyte antigen mismatch, and opportunistic infections. The end result of these insults is endothelial injury in the kidney and other organs. Recent studies also indicate a role of complement activation in tissue damage. The lack of sensitive and specific diagnostic tests for TA-TMA often results in delayed diagnosis. Biopsy is not always possible for diagnosis because of the risk of complications such as bleeding. Recently, an emerging role of renal-centered screening approach has been demonstrated, which utilize the monitoring of blood pressure, urine protein, serum lactate dehydrogenase and hemogram for early detection. Therapeutic options are limited, and plasma exchange plays a minor role. Withdrawal of offending agent such as CNIs and the use of rituximab can be effective in some patients. However, the current treatment strategy is suboptimal and associated with high mortality rate. Recently, eculizumab has been utilized in a few patients with good outcomes. Patients, who develop TA-TMA, are also at an increased risk of GVHD, infection, renal, cardiovascular, and other complications, which can contribute to high mortality. Better understanding of molecular pathogenesis, improvement in posttransplant management, leading to early diagnosis, and management of TA-TMA are required to improve outcomes of this fatal entity.

Original languageEnglish (US)
Pages (from-to)12-20
Number of pages9
JournalClinical and Applied Thrombosis/Hemostasis
Volume22
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

Thrombotic Microangiopathies
Hematopoietic Stem Cells
Transplants
Graft vs Host Disease
Kidney
Cardiovascular Infections
Plasma Exchange
Fatal Outcome
Mortality
Complement Activation
Delayed Diagnosis
Opportunistic Infections
HLA Antigens
Hemolysis
L-Lactate Dehydrogenase
Routine Diagnostic Tests
Acute Kidney Injury
Thrombocytopenia
Blood Proteins
Early Diagnosis

Keywords

  • calcineurin inhibitor
  • complement blockade
  • graft-versus-host disease
  • hematopoietic stem cell transplant
  • thrombotic microangiopathy

ASJC Scopus subject areas

  • Hematology

Cite this

Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy. / Elsallabi, Osama; Bhatt, Vijaya R; Dhakal, Prajwal; Foster, Kirk W; Tendulkar, Ketki K.

In: Clinical and Applied Thrombosis/Hemostasis, Vol. 22, No. 1, 01.01.2016, p. 12-20.

Research output: Contribution to journalArticle

@article{29ceee9626e54cb6bcb62cc42de7827d,
title = "Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy",
abstract = "Hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) is a fatal, multifactorial disorder, which may present with thrombocytopenia, hemolysis, acute renal failure, mental status changes and involvement of other organs. The pathogenesis of TA-TMA is complex and includes multiple risk factors such as certain conditioning regimens, calcineurin inhibitors (CNIs), graft-versus-host disease (GVHD), human leukocyte antigen mismatch, and opportunistic infections. The end result of these insults is endothelial injury in the kidney and other organs. Recent studies also indicate a role of complement activation in tissue damage. The lack of sensitive and specific diagnostic tests for TA-TMA often results in delayed diagnosis. Biopsy is not always possible for diagnosis because of the risk of complications such as bleeding. Recently, an emerging role of renal-centered screening approach has been demonstrated, which utilize the monitoring of blood pressure, urine protein, serum lactate dehydrogenase and hemogram for early detection. Therapeutic options are limited, and plasma exchange plays a minor role. Withdrawal of offending agent such as CNIs and the use of rituximab can be effective in some patients. However, the current treatment strategy is suboptimal and associated with high mortality rate. Recently, eculizumab has been utilized in a few patients with good outcomes. Patients, who develop TA-TMA, are also at an increased risk of GVHD, infection, renal, cardiovascular, and other complications, which can contribute to high mortality. Better understanding of molecular pathogenesis, improvement in posttransplant management, leading to early diagnosis, and management of TA-TMA are required to improve outcomes of this fatal entity.",
keywords = "calcineurin inhibitor, complement blockade, graft-versus-host disease, hematopoietic stem cell transplant, thrombotic microangiopathy",
author = "Osama Elsallabi and Bhatt, {Vijaya R} and Prajwal Dhakal and Foster, {Kirk W} and Tendulkar, {Ketki K}",
year = "2016",
month = "1",
day = "1",
doi = "10.1177/1076029615598221",
language = "English (US)",
volume = "22",
pages = "12--20",
journal = "Clinical and Applied Thrombosis/Hemostasis",
issn = "1076-0296",
publisher = "SAGE Publications Inc.",
number = "1",

}

TY - JOUR

T1 - Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy

AU - Elsallabi, Osama

AU - Bhatt, Vijaya R

AU - Dhakal, Prajwal

AU - Foster, Kirk W

AU - Tendulkar, Ketki K

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) is a fatal, multifactorial disorder, which may present with thrombocytopenia, hemolysis, acute renal failure, mental status changes and involvement of other organs. The pathogenesis of TA-TMA is complex and includes multiple risk factors such as certain conditioning regimens, calcineurin inhibitors (CNIs), graft-versus-host disease (GVHD), human leukocyte antigen mismatch, and opportunistic infections. The end result of these insults is endothelial injury in the kidney and other organs. Recent studies also indicate a role of complement activation in tissue damage. The lack of sensitive and specific diagnostic tests for TA-TMA often results in delayed diagnosis. Biopsy is not always possible for diagnosis because of the risk of complications such as bleeding. Recently, an emerging role of renal-centered screening approach has been demonstrated, which utilize the monitoring of blood pressure, urine protein, serum lactate dehydrogenase and hemogram for early detection. Therapeutic options are limited, and plasma exchange plays a minor role. Withdrawal of offending agent such as CNIs and the use of rituximab can be effective in some patients. However, the current treatment strategy is suboptimal and associated with high mortality rate. Recently, eculizumab has been utilized in a few patients with good outcomes. Patients, who develop TA-TMA, are also at an increased risk of GVHD, infection, renal, cardiovascular, and other complications, which can contribute to high mortality. Better understanding of molecular pathogenesis, improvement in posttransplant management, leading to early diagnosis, and management of TA-TMA are required to improve outcomes of this fatal entity.

AB - Hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) is a fatal, multifactorial disorder, which may present with thrombocytopenia, hemolysis, acute renal failure, mental status changes and involvement of other organs. The pathogenesis of TA-TMA is complex and includes multiple risk factors such as certain conditioning regimens, calcineurin inhibitors (CNIs), graft-versus-host disease (GVHD), human leukocyte antigen mismatch, and opportunistic infections. The end result of these insults is endothelial injury in the kidney and other organs. Recent studies also indicate a role of complement activation in tissue damage. The lack of sensitive and specific diagnostic tests for TA-TMA often results in delayed diagnosis. Biopsy is not always possible for diagnosis because of the risk of complications such as bleeding. Recently, an emerging role of renal-centered screening approach has been demonstrated, which utilize the monitoring of blood pressure, urine protein, serum lactate dehydrogenase and hemogram for early detection. Therapeutic options are limited, and plasma exchange plays a minor role. Withdrawal of offending agent such as CNIs and the use of rituximab can be effective in some patients. However, the current treatment strategy is suboptimal and associated with high mortality rate. Recently, eculizumab has been utilized in a few patients with good outcomes. Patients, who develop TA-TMA, are also at an increased risk of GVHD, infection, renal, cardiovascular, and other complications, which can contribute to high mortality. Better understanding of molecular pathogenesis, improvement in posttransplant management, leading to early diagnosis, and management of TA-TMA are required to improve outcomes of this fatal entity.

KW - calcineurin inhibitor

KW - complement blockade

KW - graft-versus-host disease

KW - hematopoietic stem cell transplant

KW - thrombotic microangiopathy

UR - http://www.scopus.com/inward/record.url?scp=84951271153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951271153&partnerID=8YFLogxK

U2 - 10.1177/1076029615598221

DO - 10.1177/1076029615598221

M3 - Article

C2 - 26239316

AN - SCOPUS:84951271153

VL - 22

SP - 12

EP - 20

JO - Clinical and Applied Thrombosis/Hemostasis

JF - Clinical and Applied Thrombosis/Hemostasis

SN - 1076-0296

IS - 1

ER -